List of Tables
Summary Table: Global Viral Vector Vaccine Manufacturing Market, by Type, Through 2022
Table 1: Characteristics of Potential Viral Vaccine Vectors
Table 2: Advantages and Disadvantages of Major Viral Vectors
Table 3: Global Market Shares of Viral Vector Vaccine Manufacturing, by Type, 2016 vs. 2022
Table 4: Global Market Shares of Viral Vector Vaccine Manufacturing, by Application Type, 2016 and 2022
Table 5: Global Market Shares of Viral Vector Vaccine Manufacturing, by Disease Segment, 2016 and 2022
Table 6: Vaccine Designs and Strategies for Their Utility Against HIV
Table 7: Global Market Shares of Viral Vector Vaccine Manufacturing, by Region, 2016 and 2022
Table 8: Driver Impact Analysis for Global Viral Vector Vaccine Manufacturing Market
Table 9: List of Clinical Trials with Their Conditions and Interventions
Table 10: Distribution of Diseases Targeted by Prophylactic Gene-Based Vaccines
Table 11: Properties of Various Viral Vectors and Their Application in Gene Therapy
Table 12: Global Incidence of Chronic Diseases, 2005-2030
Table 13: Global Prevalence of Colon Cancer, by Age Group, 2016
Table 14: Global Incidence of HIV Disease, by Region, 2016
Table 15: Various Types of Viral Vectors Used in Gene Therapy and Their Advantages
Table 16: Characteristics of Key Viral Vectors
Table 17: Global Viral Vector Vaccine Manufacturing Market, by Type, Through 2022
Table 18: Global Adenoviral Vector Vaccine Manufacturing Market, by Region, Through 2022
Table 19: Global Retroviral Vector Vaccine Manufacturing Market, by Region, Through 2022
Table 20: Advantages and Disadvantages of Retroviral Vectors
Table 21: List of Retroviral Vector Vaccines under Development as of March 2018
Table 22: Components of HIV Provirus
Table 23: Clinical Trials Deploying Lentiviral Vectors for Modification of Hematopoietic Stem Cells by Phase
Table 24: Global Lentiviral Vector Vaccine Manufacturing Market, by Region, Through 2022
Table 25: Second- versus Third-Generation Lentiviral Systems
Table 26: Selected AAV Vectors with Their Tropisms and Receptors
Table 27: Global Adeno-associated Vector Vaccine Manufacturing Market, by Region, Through 2022
Table 28: Global Cytomegalovirus Vector Vaccine Manufacturing Market, by Region, Through 2022
Table 29: Human Cytomegalovirus Vaccine Candidates in Different Stages of Preclinical and Clinical Development
Table 30: Licensed Fowl Pox Viral-Vectored Veterinary Vaccines
Table 31: Global Pox Virus Vector Vaccine Manufacturing Market, by Region, Through 2022
Table 32: Benefits and Drawbacks of HSV Viral Vectors
Table 33: Global Other Viral Vector Vaccines Manufacturing Market, by Region, Through 2022
Table 34: HSV Proposed Vaccines and Their Characteristics
Table 35: Global Viral Vector Vaccine Manufacturing Market, by Disease Segment, Through 2022
Table 36: Licensed Viral and Bacterial Vaccines for Use in Humans
Table 37: Global Viral Vector Vaccine Manufacturing Market, by Human Disease Application, Through 2022
Table 38: Global Viral Vector Manufacturing Market in Human Disease, by Region, Through 2022
Table 39: Pricing in Gavi Countries: Product-Specific Commitments
Table 40: Estimated New Cases of HAV
Table 41: Number of Death Certificates Listing HAV, HBC and HCV as a Cause of Death, 2015 and 2016
Table 42: Prevalence of HBV Infection (HBSAG) in the General Population, by WHO Region, 2015
Table 43: Leading Sites of Estimated New Cancer Cases in U.S, 2017
Table 44: Virus-Vectored Experimental Influenza Vaccines
Table 45: Some of the Delivery Vectors Evaluated in Clinical Studies for HIV Vaccines
Table 46: People Living with HIV, by Region, 2016
Table 47: Tuberculosis Viral Vector Vaccine Candidates
Table 48: Ongoing Preclinical Development and Clinical Trials on Malaria Vaccines
Table 49: Top 10 Priority Initiatives for Malaria Vaccine Development According to the Malaria Vaccine Technology Roadmap
Table 50: Ongoing Clinical Trials of Vector Vaccines against EVD, As of 2017
Table 51: EVD Cases and Death, by Country
Table 52: Zika Virus Vaccine Development and Ongoing Clinical Trials
Table 53: Licensed Viral-Vectored Veterinary Vaccines
Table 54: Global Estimates of the Growth in Demand for Meat, 2010-2030
Table 55: Global Viral Vector Vaccine Manufacturing Market, by Veterinary Disease Application, Through 2022
Table 56: Global Viral Vector Vaccine Manufacturing Market for Veterinary Disease Application, by Region, Through 2022
Table 57: Avian Influenza Vaccines
Table 58: Global Estimates of Poultry Production
Table 59: Marek’s Disease Vaccines
Table 60: Grants Supporting the Development of Novel Recombinant Adenovirus-Based Vaccine Candidates for Respiratory Diseases in Chickens
Table 61: Global Viral Vector Vaccine Manufacturing Market, by Application, Through 2022
Table 62: Comparison of the Viral Vectors Discussed Based on Specific Vector Characteristics
Table 63: Global Multivalent Viral Vector Vaccine Manufacturing Market, by Region, Through 2022
Table 64: Global Incidence of HIV Disease, by Region, 2015 and 2016
Table 65: Global Incidence of TB, by Region, 2016
Table 66: Global Multipathogen Viral Vector Vaccine Manufacturing Market, by Region, Through 2022
Table 67: Overview of Multivalent/Polyvalent and Multipathogen/Multidisease Viral Vector Vaccine Candidates, by Vector
Table 68: Global Viral Vector Vaccine Manufacturing Market, by Region, Through 2022
Table 69: North American Viral Vector Vaccine Manufacturing Market, by Country, Through 2022
Table 70: North American Viral Vector Manufacturing Market, by Type, Through 2022
Table 71: Cancer Research Funding in the U.S., 2015 and 2016
Table 72: North American Viral Vector Manufacturing Market, by Application Type, Through 2022
Table 73: U.S. Viral Vector Vaccine Manufacturing Market, by Type, Through 2022
Table 74: North American Viral Vector Manufacturing Market, by Disease Segment, Through 2022
Table 75: NIH Funding for CRISPR-Related Research, 2006-2016
Table 76: North American Viral Vector Manufacturing Market, by Human Disease Application, Through 2022
Table 77: New HIV Diagnoses in the U.S., by Age Group, 2016
Table 78: Viral Vector Vaccines in Development in U.S.
Table 79: Canadian Viral Vector Vaccine Manufacturing Market, by Type, Through 2022
Table 80: North American Viral Vector Manufacturing Market, by Veterinary Disease Application, Through 2022
Table 81: Confirmed Influenza Cases in Mexico, 2012-2016
Table 82: Mexican Viral Vector Vaccine Manufacturing Market, by Type, Through 2022
Table 83: European Viral Vector Vaccine Manufacturing Market, by Country, Through 2022
Table 84: Losses Due to HPAI Outbreaks in Domestic Birds, by Region, January 2013-January 2018
Table 85: Recent Impact of HPAI in Domestic Birds, by Region, February 2018
Table 86: German Viral Vector Vaccine Manufacturing Market, by Type, Through 2022
Table 87: European Viral Vector Manufacturing Market, by Type, Through 2022
Table 88: U.K. Viral Vector Vaccine Manufacturing Market, by Type, Through 2022
Table 89: European Viral Vector Manufacturing Market, by Application Type, Through 2022
Table 90: HIV/AIDS Statistics in the U.K., 2015
Table 91: People Living with HIV (All Ages) in France, 2000-2016
Table 92: French Viral Vector Vaccine Manufacturing Market, by Type, Through 2022
Table 93: Distribution of the Leading Causes of Death in Women in France, 2017
Table 94: Distribution of the Leading Causes of Death in Men in France, 2017
Table 95: European Viral Vector Manufacturing Market, by Disease Segment, Through 2022
Table 96: European Viral Vector Manufacturing Market, by Human Disease Application, Through 2022
Table 97: HPAI Outbreaks in Poultry and Wild Bird Cases in the E.U., October 2016 - July 2017
Table 98: European Viral Vector Manufacturing Market, by Veterinary Disease Application, Through 2022
Table 99: Spanish Viral Vector Vaccine Manufacturing Market, by Type, Through 2022
Table 100: Number of People in Spain Infected with HIV, by Age, 2000-2016
Table 101: Italian Viral Vector Vaccine Manufacturing Market, by Type, Through 2022
Table 102: Italian Poultry Meat Production, 2016
Table 103: Rest of Europe Viral Vector Vaccine Manufacturing Market, by Type, Through 2022
Table 104: Number of People Infected with HIV in Select Countries in the Rest of Europe Region, 2000-2016
Table 105: Asia-Pacific Viral Vector Vaccine Manufacturing Market, by Country, Through 2022
Table 106: Asia-Pacific Viral Vector Manufacturing Market, by Type, Through 2022
Table 107: Chinese Viral Vector Vaccine Manufacturing Market, by Type, Through 2022
Table 108: Asia-Pacific Viral Vector Manufacturing Market, by Application Type, Through 2022
Table 109: Ongoing Preclinical and Clinical Trials of HIV/AIDS Vaccine in China
Table 110: Asia-Pacific Viral Vector Manufacturing Market, by Disease Segment, Through 2022
Table 111: Confirmed Cases of Human Infection with Avian Influenza in China, 2013 and 2016
Table 112: Asia-Pacific Viral Vector Manufacturing Market, by Human Disease Application, Through 2022
Table 113: Indian Viral Vector Vaccine Manufacturing Market, by Type, Through 2022
Table 114: Prevalence of Tuberculosis Cases in India, 2016
Table 115: Asia-Pacific Viral Vector Manufacturing Market, by Veterinary Disease Application, Through 2022
Table 116: Ongoing Clinical Trials Related to HIV Vaccines in India
Table 117: Japanese Viral Vector Vaccine Manufacturing Market, by Type, Through 2022
Table 118: Reported Cumulative Number of HIV Cases in Japan, 2012 and 2016
Table 119: Australian Viral Vector Vaccine Manufacturing Market, by Type, Through 2022
Table 120: Various Viral Vaccine Vectors Used in AIDS Vaccine Development
Table 121: Number of Newly Diagnosed Cases of HIV Infection in Australia, 2012-2016
Table 122: South Korean Viral Vector Vaccine Manufacturing Market, by Type, Through 2022
Table 123: HPAI Outbreaks in South Korea, 2003-2017
Table 124: Vaccine Strains for Immunization of Chickens against H5N1 HPAIVS
Table 125: Distribution of Causes of Death in South Korea, 2016
Table 126: Rest of APAC Viral Vector Vaccine Manufacturing Market, by Type, Through 2022
Table 127: Leading Causes of Deaths in Singapore, 2014-2016
Table 128: Mortality by Sex and Cause of Death, 2016
Table 129: HIV/AIDS Statistics for Thailand, 2016
Table 130: Ongoing Clinical Trials for Preventive HIV Vaccine Candidates in Thailand
Table 131: Estimated Worldwide Rates of Skin Cancer per Capita
Table 132: Newly Diagnosed HIV Cases in the Philippines, by Age Group, 2016
Table 133: Number of Newly Diagnosed HIV Cases per Day in the Philippines, 2008-2017
Table 134: ROW Viral Vector Vaccine Manufacturing Market, by Region, Through 2022
Table 135: ROW Viral Vector Manufacturing Market, by Type, Through 2022
Table 136: Latin American Viral Vector Vaccine Manufacturing Market, by Type, Through 2022
Table 137: Poultry Consumption across ROW Countries, 2017
Table 138: ROW Viral Vector Manufacturing Market by Application Type Through 2022
Table 139: Top 10 Causes of Deaths in Cuba and Percentage Change from 2005 to 2016
Table 140: Middle East and African Viral Vector Vaccine Manufacturing Market, by Type, Through 2022
Table 141: ROW Viral Vector Manufacturing Market, by Disease Segment, 2017-2022
Table 142: Characteristics of the Priority Diseases Identified in the WHO R&D Blueprint, Revised, 2017
Table 143: ROW Viral Vector Manufacturing Market, by Human Disease Application, Through 2022
Table 144: ROW Viral Vector Manufacturing Market, by Veterinary Disease Application, Through 2022
Table 145: Viral Vector Overview
Table 146: Related Impurities to be Eliminated, by Downstream Processing
Table 147: Viral Vector Manufacturing Suppliers
Table 148: List of Some of the Viral Vector Producers
Table 149: List of Company Expansion
Table 150: List of Collaborations
Table 151: List of Investments
Table 152: List of Acquisitions
Table 153: U.S. Viral Vector Vaccine Manufacturing Patents, 2015-May 2018
Table 154: European Viral Vector Vaccine Manufacturing Patents, 2015-May 2018
Table 155: Japanese Viral Vector Vaccine Manufacturing Patents, 2015-May 2018
Table 156: Advanced BioScience Laboratories Product Portfolio
Table 157: Advanced BioScience Laboratories Recent Developments, 2015-April 2018
Table 158: Advanced Biotherapeutics Consulting Product Portfolio
Table 159: Applied Viromics Product Portfolio
Table 160: Batavia Biosciences Product Portfolio
Table 161: Batavia Bioscience Recent Developments, 2015-April 2018
Table 162: Benitec Biopharma Product Portfolio
Table 163: Biogen Product Portfolio
Table 164: Biogen Recent Developments, 2015-April 2018
Table 165: Biovian Product Portfolio
Table 166: Boehringer Ingelheim Product Portfolio
Table 167: Brammer Bio Product Portfolio
Table 168: Brammer Bio Recent Developments, 2015-April 2018
Table 169: Cell and Gene Therapy Catapult Product Portfolio
Table 170: Cell and Gene Therapy Catapult Recent Developments, 2015 - April 2018
Table 171: Ceva Product Portfolio
Table 172: Cobra Biologics Product Portfolio
Table 173: Cobra Biologics Recent Developments, 2015 - April 2018
Table 174: Creative Biogene Product Portfolio
Table 175: GE Healthcare Product Portfolio
Table 176: GeneDetect Product Portfolio
Table 177: GenVec Product Portfolio
Table 178: ID Pharma Product Portfolio
Table 179: Janssen Product Portfolio
Table 180: Janssen Recent Developments, 2015 - April 2018
Table 181: Lonza Group Product Portfolio
Table 182: Lonza Group Recent Developments, 2015 - April 2018
Table 183: Merck Millipore Product Portfolio
Table 184: Merck Millipore Recent Developments, 2015 - April 2018
Table 185: Miltenyi Biotec Product Portfolio
Table 186: MolMed Product Portfolio
Table 187: Paragon Bioservices Product Portfolio
Table 188: Paragon Bioservices Recent Developments, 2015 - April 2018
Table 189: Pfizer Product Portfolio
Table 190: Pfizer Recent Developments, 2015 - April 2018
Table 191: Sanofi Product Portfolio
Table 192: Sementis Product Portfolio
Table 193: Spark Therapeutics Product Portfolio
Table 194: Spark Therapeutics Recent Developments, 2015 - April 2018
Table 195: Synpromics Product Portfolio
Table 196: Synpromics Recent Developments, 2015 - April 2018
Table 197: Valneva Product Portfolio
Table 198: Vector Biolabs Product Portfolio
Table 199: Vigene Biosciences Product Portfolio
Table 200: Vigene Biosciences Recent Developments, 2015 - April 2018
Table 201: Virovek Product Portfolio
List of Figures
Summary Figure: Global Viral Vector Vaccine Manufacturing Market, by Type, 2017-2022
Figure 1: Notable Vaccine Advancements
Figure 2: Vaccine Research Cycle
Figure 3: WHO Mandatory Steps for Vaccine Approval
Figure 4: FDA Stages of Vaccine Review and Regulation
Figure 5: EMA Stages of Vaccine Review and Regulation
Figure 6: MHLW Stages of Vaccine Review and Regulation
Figure 7: Vaccine Approval Process in India
Figure 8: Life Cycle of Virus in Cells
Figure 9: Key Properties of Viral Vector
Figure 10: Global Market Shares of Viral Vector Vaccine Manufacturing, by Type, 2016 and 2022
Figure 11: Working of an Ad-Vector Vaccine
Figure 12: Role of CMV in Immunosenesce of Humans
Figure 13: Global Market Shares of Viral Vector Vaccine Manufacturing, by Application Type, 2016 - 2022
Figure 14: Global Market Shares of Viral Vector Vaccine Manufacturing, by Disease Segment, 2016 and 2022
Figure 15: Global Market Shares of Viral Vector Vaccine Manufacturing, by Region, 2016 and 2022
Figure 16: Distribution of Diseases Targeted by Prophylactic Gene-Based Vaccines
Figure 17: Global Incidence of Chronic Diseases 2005-2030
Figure 18: Global Prevalence of Colon Cancer, by Age Group, 2016
Figure 19: Global Incidence of HIV Disease, by Region, 2016
Figure 20: Structure of Third-Generation Lentiviral Vectors
Figure 21: Prevalence of HBV Infection (HBSAG) in the General Population, by WHO Region, 2015
Figure 22: People Living with HIV, by Region, 2016
Figure 23: EVD Cases and Death, by Country
Figure 24: Global Estimates of the Growth in Demand for Meat, 2010-2030
Figure 25: Global Shares of Demand for Meat, 2010 and 2030
Figure 26: Global Estimates of Poultry Production
Figure 27: Schematic Overview of Multipathogen/Multidisease and Multivalent/Polyvalent Viral Vector Vaccines
Figure 28: Global Incidence of HIV Disease, by Region, 2015 and 2016
Figure 29: Comparative Analysis of Regional Market Shares, 2016 vs. 2022
Figure 30: New HIV Diagnoses in the U.S., by Age Group, 2016
Figure 31: Confirmed Influenza Cases in Mexico, 2012-2016
Figure 32: Losses Due to HPAI Outbreaks in Domestic Birds, by Region, January 2013-January 2018
Figure 33: People Living with HIV (All Ages) in France, 2000-2016
Figure 34: Distribution of the Leading Causes of Death in Women in France, 2017
Figure 35: Distribution of the Leading Causes of Death in Men in France, 2017
Figure 36: Number of People in Spain Infected with HIV, by Age, 2000-2016
Figure 37: Italian Poultry Meat Production, 2016
Figure 38: Number of People Infected with HIV in Select Countries in the Rest of Europe Region, 2000-2016
Figure 39: Confirmed Human Infection with Avian Influenza in China, 2013 and 2016
Figure 40: Reported Cumulative Number of HIV Cases in Japan, 2012 and 2016
Figure 41: Number of Newly Diagnosed Cases of HIV Infection in Australia, 2012-2016
Figure 42: Distribution of Causes of Death in South Korea, 2016
Figure 43: Estimated Worldwide Rates of Skin Cancer per Capita
Figure 44: Newly Diagnosed HIV Cases in the Philippines, by Age Group, 2016
Figure 45: Number of Newly Diagnosed HIV Cases per Day in the Philippines, 2008-2017
Figure 46: Poultry Consumption Across ROW Countries, 2017
Figure 47: Features of Vectors
Figure 48: Key Properties of Viral Vectors
Figure 49: Common Viral-Vector Manufacturing Process
Figure 50: Viral Vector Manufacturing Process
Figure 51: Adenovirus Manufacturing Process
Figure 52: Viral-Vector Vaccine Manufacturing Industry
Figure 53: Level of Impact of Manufacturer Purchasing Criteria, 2018-2022
Figure 54: Shares of Competitive Landscape, 2015-2018
